000304123 001__ 304123
000304123 005__ 20251203143134.0
000304123 0247_ $$2doi$$a10.1002/ijc.70090
000304123 0247_ $$2pmid$$apmid:40857027
000304123 0247_ $$2ISSN$$a0020-7136
000304123 0247_ $$2ISSN$$a1097-0215
000304123 037__ $$aDKFZ-2025-01786
000304123 041__ $$aEnglish
000304123 082__ $$a610
000304123 1001_ $$00000-0002-2129-0911$$aPham, Thu Thi$$b0
000304123 245__ $$aCirculating fatty acid binding protein 4 (FABP-4) concentrations and mortality in individuals with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study.
000304123 260__ $$aBognor Regis$$bWiley-Liss$$c2026
000304123 3367_ $$2DRIVER$$aarticle
000304123 3367_ $$2DataCite$$aOutput Types/Journal article
000304123 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764768654_1331671
000304123 3367_ $$2BibTeX$$aARTICLE
000304123 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304123 3367_ $$00$$2EndNote$$aJournal Article
000304123 500__ $$a2026 Feb 1;158(3):546-559
000304123 520__ $$aHuman fatty acid binding protein-4 (FABP-4), a protein elevated in obesity that promotes colon cancer cell invasiveness and metastasis, may be associated with higher mortality in individuals with colorectal cancer (CRC) and may serve as a mediator of the obesity-mortality association in these individuals. We used a causal diagram to inform covariate selection and applied Cox proportional hazards models to estimate hazard ratios (HRs) for CRC-specific, non-CRC-specific, and all-cause mortality by FABP-4 levels measured in baseline blood samples from 1371 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. Competing risk analyses were adapted for CRC and non-CRC deaths. Mediation analyses were conducted to estimate total effects (TEs), direct effects (DEs), and mediation proportions (MPs) by FABP-4 of pre-diagnostic body mass index (BMI) on mortality. In the fully adjusted model including BMI, higher circulating FABP-4 concentrations were associated with higher CRC mortality (HRQ4vsQ1 = 1.49; 95% CI: 1.11-2.00) and all-cause mortality (HRQ4vsQ1 = 1.49; 95% CI: 1.15-1.93), but not statistically associated with non-CRC mortality (HRQ4vsQ1 = 1.51; 95% CI: 0.82-2.76). The TE and DE per 5 kg/m2 of BMI on all-cause mortality were 1.21; 95% CI: 1.10-1.34, and 1.13; 95% CI: 1.02-1.26, respectively, with a MP of 34.5% (p = .002) by FABP-4. For CRC-specific and non-CRC-specific mortality, MPs by FABP-4 were 33.7% (p = .03) and 36.1% (p = .02), respectively. In conclusion, higher concentrations of FABP-4 were associated with higher CRC-specific and all-cause mortality in individuals with CRC. FABP-4 was a significant partial mediator of the adiposity-mortality relationship in individuals with CRC.
000304123 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000304123 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304123 650_7 $$2Other$$aEPIC
000304123 650_7 $$2Other$$aFABP‐4
000304123 650_7 $$2Other$$ahuman fatty acid binding protein‐4
000304123 650_7 $$2Other$$aincident colorectal cancer
000304123 650_7 $$2Other$$amortality
000304123 7001_ $$00000-0001-7877-205X$$aNimptsch, Katharina$$b1
000304123 7001_ $$00000-0002-1275-1827$$aAleksandrova, Krasimira$$b2
000304123 7001_ $$00000-0002-0573-1852$$aJenab, Mazda$$b3
000304123 7001_ $$00000-0002-7805-9913$$aFedirko, Veronika$$b4
000304123 7001_ $$aOlsen, Anja$$b5
000304123 7001_ $$aTjønneland, Anne$$b6
000304123 7001_ $$aCadeau, Claire$$b7
000304123 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b8
000304123 7001_ $$aSchulze, Matthias B$$b9
000304123 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b10$$udkfz
000304123 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b11$$udkfz
000304123 7001_ $$aAgnoli, Claudia$$b12
000304123 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b13
000304123 7001_ $$aTumino, Rosario$$b14
000304123 7001_ $$aSignoriello, Simona$$b15
000304123 7001_ $$aTrobajo-Sanmartín, Camino$$b16
000304123 7001_ $$aGómez, Jesús-Humberto$$b17
000304123 7001_ $$aChirlaque, María-Dolores$$b18
000304123 7001_ $$aSánchez, Maria-Jose$$b19
000304123 7001_ $$aCrous-Bou, Marta$$b20
000304123 7001_ $$aMay, Anne$$b21
000304123 7001_ $$00000-0001-6517-1300$$aHeath, Alicia$$b22
000304123 7001_ $$00000-0002-4533-1722$$aAune, Dagfinn$$b23
000304123 7001_ $$aWeiderpass, Elisabete$$b24
000304123 7001_ $$aPischon, Tobias$$b25
000304123 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70090$$gp. ijc.70090$$n3$$p546-559$$tInternational journal of cancer$$v158$$x0020-7136$$y2026
000304123 909CO $$ooai:inrepo02.dkfz.de:304123$$pVDB
000304123 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000304123 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000304123 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000304123 9141_ $$y2025
000304123 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000304123 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000304123 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000304123 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000304123 9201_ $$0I:(DE-He78)C180-20160331$$kC180$$lKrebsepidemiologie$$x0
000304123 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x1
000304123 980__ $$ajournal
000304123 980__ $$aVDB
000304123 980__ $$aI:(DE-He78)C180-20160331
000304123 980__ $$aI:(DE-He78)C020-20160331
000304123 980__ $$aUNRESTRICTED